What question did this study set out to answer?

To evaluate the impact of adjuvant imatinib therapy on recurrence-free survival in different genotypes of resected gastrointestinal stromal tumors.

Clinical outcomes of resected gastrointestinal stromal tumors treated with 3 years of adjuvant imatinib in different genotypes.

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows improved recurrence-free survival with imatinib in wild-type and mutation GISTs.

To evaluate the impact of adjuvant imatinib therapy on recurrence-free survival in different genotypes of resected gastrointestinal stromal tumors.
Retrospective analysis of 468 patients with high-risk resectable GISTs
Patients either received or did not receive 3 years of adjuvant imatinib
Recurrence-free survival assessed using Kaplan–Meier estimates and Cox regression models
Three years of adjuvant imatinib significantly improved RFS (HR 0.33; p < 0.001)
Subgroup analysis showed RFS benefits in KIT exon 11 (HR 0.32) and KIT exon 9 mutations (HR 0.32)
Five-year RFS rates higher with imatinib across genotypes, e.g., KIT exon 11 (59.9% vs 22.0%)

Kim et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark